Portage Biotech (NASDAQ:ALP) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Portage Biotech (NASDAQ:ALP) to a hold rating in a report released on Tuesday morning,Zacks.com reports.

Several other research firms have also recently commented on ALP. Weiss Ratings reissued a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. HC Wainwright initiated coverage on shares of Portage Biotech in a report on Monday. They issued a “neutral” rating and a $0.25 price objective for the company. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $0.25.

Portage Biotech Stock Down 7.1%

ALP opened at $0.15 on Tuesday. The stock’s 50 day moving average price is $0.28 and its 200 day moving average price is $0.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The stock has a market cap of $3.54 million, a P/E ratio of -0.02 and a beta of 0.61. Portage Biotech has a 12 month low of $0.14 and a 12 month high of $13.80.

Portage Biotech (NASDAQ:ALP) last released its quarterly earnings results on Thursday, July 16th. The company reported $0.48 earnings per share (EPS) for the quarter. The business had revenue of $0.05 million during the quarter. As a group, research analysts predict that Portage Biotech will post -0.28 earnings per share for the current year.

Portage Biotech News Roundup

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright’s $0.25 price target is above Portage Biotech’s recent trading level, suggesting meaningful theoretical upside if the company executes on its development plans. The firm also expects losses to narrow from an estimated $(0.28) per share in fiscal 2027 to $(0.17) in fiscal 2028.
• Neutral Sentiment: HC Wainwright forecasts quarterly losses of $(0.10), $(0.07), $(0.07), and $(0.06) per share for fiscal 2027, resulting in a $(0.28) full-year loss. For fiscal 2028, the analyst projects a relatively consistent $(0.04) quarterly loss and a $(0.17) annual loss, indicating gradual improvement but no expected profitability in the forecast period. Portage Biotech analyst estimates
• Negative Sentiment: The Neutral rating and continuing projected losses may limit investor enthusiasm. Portage Biotech has also experienced substantial share-price weakness, trading close to its one-year low, while its latest reported quarterly revenue was only $0.05 million.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.